Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico
PLOS ONE · 07.02.2025 · 20 (2) · e0299673
DOI: 10.1371/journal.pone.0299673 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 07.02.2025. Verfasst von Juan Pablo Diaz Martinez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Osteoporosis, Postmenopausal, Antibodies, Monoclonal, Bone Density Conservation Agents, Fractures, Bone. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen Mexico.
Abstract (Originalsprache)
Introduction
This study aims to assess the cost effectiveness of romosozumab versus teriparatide, both sequenced to denosumab, for the treatment of severe postmenopausal osteoporosis at very high risk of fractures in Mexican women.
Methods
A Markov model was used to assess the relative cost effectiveness of 1 year of romosozumab versus 2 years of teriparatide, both sequenced to denosumab for a total treatment duration of 5 years. Outcomes for a cohort of women with a mean age of 74 years, a T-score ≤-2.5 and a previous fragility fracture were simulated over a lifetime horizon. The analysis was conducted from the perspective of the Mexican healthcare system and used a discount rate of 5% per annum. To inform relative fracture incidence, the bone mineral density (BMD) advantage of romosozumab over teriparatide was translated into relative risks of fracture, using relationships provided by a meta-regression of osteoporosis therapy trials. Outcomes were assessed in terms of lifetime costs (2023 Mexican pesos), quality-adjusted life years (QALYs) and life-years gained (LYs).
Results
Base case results showed that, compared with teriparatide/ denosumab, romosozumab/ denosumab reduced costs by $51,363 MXN per patient and yielded 0.03 additional QALYs and 0.01 LYs. Scenario analyses and probabilistic sensitivity analyses confirmed that results are robust to uncertainty in model assumptions and inputs.
Conclusions
Results show that romosozumab/ denosumab produces greater health benefits at a lower total cost than teriparatide/ denosumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.
- Health Economics Amgen Mexico, Mexico City, Mexico.
- Health Economics Amgen, Thousand Oaks, CA, United States of America.
ORCID-Profile: Juan Pablo Diaz Martinez
Förderung
- Amgen Mexico
Zitieren
APA
Diaz Martinez, J. P., Aubry de Maraumont, T., Natty Sánchez, E., Camacho Cordero, L. M., & Yeh, E. (2025). Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico. PLOS ONE, 20(2), e0299673. https://doi.org/10.1371/journal.pone.0299673
Vancouver
Diaz Martinez JP, Aubry de Maraumont T, Natty Sánchez E, Camacho Cordero LM, Yeh E. Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico. PLOS ONE. 2025;20(2):e0299673. doi:10.1371/journal.pone.0299673
BibTeX
@article{DiazMartinez2025,
author = {Diaz Martinez, Juan Pablo and Aubry de Maraumont, Therese and Natty Sánchez, Elly and Camacho Cordero, Luis Miguel and Yeh, Eric},
title = {Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico},
journal = {PLOS ONE},
year = {2025},
volume = {20},
number = {2},
pages = {e0299673},
doi = {10.1371/journal.pone.0299673}
}
EUVIMED